- |||||||||| memantine / Generic mfg.
Journal: Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. (Pubmed Central) - Aug 11, 2022
Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. There are insufficient data to recommend for or against performing routine magnetic resonance imaging to screen for brain metastases; clinicians should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.Additional information is available at www.asco.org/breast-cancer-guidelines.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Trintellix (vortioxetine) / Lundbeck, Takeda, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal: Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning. (Pubmed Central) - Aug 11, 2022
Other drugs with long half-lives that psychiatrists may prescribe include levothyroxine and zonisamide...They also take long to wash out; this is an advantage because the risk of drug withdrawal or discontinuation syndromes is small, and a disadvantage if rapid washout is desired for any reason, including the experience of drug adverse effects or toxicity, or the discovery of an unplanned pregnancy. Other clinical issues related to drugs with long half-lives include the relevance of occasional missed doses, the possibility of once-weekly dosing, and the need for pregnancy planning.
- |||||||||| memantine / Generic mfg., cyclosporine / Generic mfg.
Journal: Calcineurin Controls Hypothalamic NMDA Receptor Activity and Sympathetic Outflow. (Pubmed Central) - Aug 10, 2022
Future studies will need to examine these results in a larger sample. Our findings reveal that normal calcineurin activity in the PVN constitutively restricts sympathetic vasomotor tone via suppressing NMDA receptor activity, which may be targeted for treating calcineurin inhibitor-induced hypertension.
- |||||||||| memantine / Generic mfg.
Journal: Alzheimer's disease medication use and adherence patterns by race and ethnicity. (Pubmed Central) - Aug 9, 2022
Compared to Whites, Blacks and Hispanics had lower use, poorer treatment adherence, and more frequent discontinuation of ADRD medication, but when controlling for disease severity and socioeconomic factors, racial disparities diminish. Our findings demonstrate the importance of adjusting for socioeconomic characteristics and disease severity when studying medication use and adherence in ADRD patients.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Journal: Reimagining cholinergic therapy for Alzheimer's disease. (Pubmed Central) - Aug 4, 2022
The classical symptomatic cholinergic therapy based on cholinesterase inhibitors is judiciously discussed for its maximal efficacy and best clinical application. The review proposes new alternatives of cholinergic therapy that should be developed to amplify its clinical effect and supplement the disease-modifying effect of new treatments to slow down or arrest disease progression.
- |||||||||| memantine / Generic mfg.
Evaluating the Utility of EQ5D-5L in Patients with Brain Metastases: Secondary Analysis of NRG-CC001 (Henry B. Gonzalez Convention Center, Room 007 C/D) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1437;
Given that NCF is well-established as a patient-centric outcome measure following brain radiation, the results of this study challenge the routine use of EQ5D in brain metastases clinical trials that are focused on preventing NCF failure. There is an urgent need to identify preference-based health status measures that are sensitive to changes in NCF and can be utilized in clinical trials for patients with brain metastases.
- |||||||||| memantine / Generic mfg.
Trial completion date, Trial primary completion date: Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (clinicaltrials.gov) - Aug 1, 2022
P3, N=100, Recruiting,
Patients with lung histology as well as those with lower baseline MDASI-BT cognitive factor scores, denoting less severe cognitive impairment at enrollment, had significantly greater benefit from HA-WBRT. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| memantine / Generic mfg.
Journal: Boron Nitride Nanoparticles Loaded with a Boron-Based Hybrid as a Promising Drug Carrier System for Alzheimer's Disease Treatment. (Pubmed Central) - Jul 30, 2022
Drug loading analyses reported that uncoated hBN nano conjugate could not load the BLA, whereas the memantine loading capacity of hBN was 84.3%...In conclusion, the developed drug carrier system for AD treatment showed promising potential for further investigations and enlightened neuroprotective capabilities of boron molecules to treat AD and other neurodegenerative diseases. On the other hand, enzyme activity, systematic toxicity analyses, and animal studies should be performed to understand neuroprotective properties of the designed carrier system comprehensively.
- |||||||||| Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
Review, Journal: Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews. (Pubmed Central) - Jul 27, 2022
The use of ChEIs, including rivastigmine, galantamine, and donepezil, as well as memantine has demonstrated a positive impact on improving cognitive outcomes of AD patients, but no considerable effects were found for immunotherapies. Melatonin, statins, antihypertensive drugs, antidiabetic agents, Cerebrolysin, psychostimulants, and some herbal drugs such as Danggui-Shaoyao-San and Ginkgo biloba seem to be effective in improving cognitive function of AD patients, but the evidence in this regard is limited.
- |||||||||| dizocilpine (MK801) / Merck (MSD)
Journal: Inhibition of NMDA receptors through a membrane-to-channel path. (Pubmed Central) - Jul 24, 2022
Here we use electrophysiological recordings from transfected tsA201 cells and cultured neurons, NMDAR structural modeling, and custom-synthesized compounds to show that NMDAR channel blockers can enter the channel through two routes: the well-known hydrophilic path from extracellular solution to channel through the open channel gate, and also a hydrophobic path from plasma membrane to channel through a gated fenestration ("membrane-to-channel inhibition" (MCI)). Our demonstration that ligand-gated channels are subject to MCI, as are voltage-gated channels, highlights the broad expression of this inhibitory mechanism.
- |||||||||| prazosin / Generic mfg.
Review, Journal: Prazosin for the management of behavioural and psychological symptoms of dementia. (Pubmed Central) - Jul 24, 2022
Given the limitations in available data, the routine use of prazosin for the treatment of BPSD cannot be recommended at this time. However, prazosin may be used for the management of agitation and aggression amongst individuals with dementia when other medication classes, like acetylcholinesterase inhibitors, memantine, antidepressants and/or atypical antipsychotics, have been ineffective or not tolerated.
- |||||||||| memantine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: MIND: Local Study of Akatinol Memantine in VaD in Russia (clinicaltrials.gov) - Jul 23, 2022
P3, N=130, Completed,
However, prazosin may be used for the management of agitation and aggression amongst individuals with dementia when other medication classes, like acetylcholinesterase inhibitors, memantine, antidepressants and/or atypical antipsychotics, have been ineffective or not tolerated. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2022 | Trial primary completion date: Dec 2022 --> Jun 2022
- |||||||||| memantine / Generic mfg.
Review, Journal: The Cognitive Effects of Radiotherapy for Brain Metastases. (Pubmed Central) - Jul 20, 2022
Furthermore, stereotactic radiosurgery (SRS) has emerged as an appealing treatment option over the last decade in the management of brain metastases and is associated with superior cognitive preservation and quality of life when compared to WBRT. This review article evaluates the pathogenesis and impact of cranial irradiation on cognition in patients with brain metastases, as well as current and future risk mitigation techniques.
- |||||||||| Review, Journal: ECT-resistant Catatonia: Case Report and Literature Review. (Pubmed Central) - Jul 17, 2022
This review article evaluates the pathogenesis and impact of cranial irradiation on cognition in patients with brain metastases, as well as current and future risk mitigation techniques. The literature review and new case suggest reconsideration of catatonia diagnosis, optimizing ECT treatments, cautious use of antipsychotics, consideration of lorazepam augmentation to ECT treatments and/or use of N-methyl-D-aspartate (NMDA) receptor antagonists.
- |||||||||| memantine / Generic mfg.
Preclinical, Journal, IO biomarker: NMDA receptor antagonists engender neuroprotection against gp120-induced cognitive dysfunction in Rats through Modulation of PKR activation, oxidative stress, ER stress and IRE1α Signal Pathway. (Pubmed Central) - Jul 17, 2022
In this study, we found that NMDAR antagonist memantine or PKR inhibitor C16 improved gp120-induced learning and memory impairment and inhibited gp120-induced PKR activity...So the NMDA receptor antagonists could alleviate HIV/gp120 induced dementia in the rat model by altering PKR level. In conclusion, this study demonstrates that NMDARs plays a key role in HIV/gp120 induced hippocampal damage and cognitive dysfunction through PKR mediated oxidative stress, ER stress, and IRE1α/JNK signaling pathway in rats, implicating PKR inhibitors could provide a novel neuroprotective strategy for HAND via inhibiting ER stress and its downstream IRE1α signaling pathway.
- |||||||||| memantine / Generic mfg.
Preclinical, Journal, IO biomarker: NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice. (Pubmed Central) - Jul 17, 2022
This study aimed to evaluate a new NMDA receptor antagonist (UB-ALT-EV) and memantine in 6-month-old female 5XFAD mice that were exposed orally to a chronic low-dose treatment...Likewise, treatment with UB-ALT-EV recovered a WT mice profile in apoptosis markers Bcl-2, Bax, and caspase-3. In conclusion, our results revealed the potential neuroprotective effect of UB-ALT-EV by attenuating NMDA-mediated apoptosis and reducing Aβ deposition and deposition jointly with the autophagy rescue to finally reduce cognitive alterations in a mice model of familial AD.
- |||||||||| riluzole / Generic mfg., trazodone ER / Generic mfg., memantine / Generic mfg.
P3 data, Journal: Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. (Pubmed Central) - Jul 15, 2022
P2/3
Despite decades of research and clinical trials there remains no cure and only one globally approved drug, riluzole, which prolongs survival by 2-3 months...The first two drugs selected for evaluation in MND-SMART are trazodone and memantine...(REC reference: 19/WS/0123) Results of the study will be submitted for publication in a peer-reviewed journal and a summary provided to participants. European Clinical Trials Registry (2019-000099-41); NCT04302870.
- |||||||||| memantine / Generic mfg.
Journal: Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. (Pubmed Central) - Jul 10, 2022
For patients with favorable prognosis and brain metastases ineligible for surgery and/or SRS, WBRT is recommended with hippocampal avoidance where possible and the addition of memantine is recommended. For patients with brain metastases, limiting the single-fraction V to brain tissue to ≤ 10 cm is conditionally recommended.Additional information is available at www.asco.org/neurooncology-guidelines.
- |||||||||| ketamine / Generic mfg., memantine / Generic mfg.
Journal: Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression. (Pubmed Central) - Jul 9, 2022
However, a more thorough examination of the effects of ketamine and memantine on cellular and synaptic function will be necessary for responsible administration. Additionally, because the effects of ketamine and memantine are highly dependent on prior drug use, traumatic stress, or a history of aggressive behavior, we propose a more thorough medical evaluation and psychiatric assessment will be necessary to avoid possible adverse interactions with these drugs.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Review, Journal: Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. (Pubmed Central) - Jun 25, 2022
In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
- |||||||||| idalopirdine (Lu AE58054) / Otsuka, Eli Lilly, Denovo
Clinical, Review, Journal, Combination therapy: Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. (Pubmed Central) - Jun 22, 2022
Fluoxetine and ST101 have shown partial benefits in combination with ChEI over ChEI monotherapy and placebo...Longer trials are needed. No major cognitive benefit is missed, if solely appropriate ChEI monotherapy is initiated.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen
Journal: Challenges and approaches of drugs such as Memantine, Donepezil, Rivastigmine and Aducanumab in the treatment, control and management of Alzheimer's disease. (Pubmed Central) - Jun 22, 2022
This review appraises the effects of memantine, donepezil, rivastigmine, and aducanumab in clinical trials, in vitro and animal model studies that have explored how these drugs versus AD development and also discuss possible mechanisms of influence on the brain. Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness.
- |||||||||| memantine / Generic mfg.
Clinical guideline: Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. (Pubmed Central) - Jun 22, 2022
Research in clinical trials has substantial findings that support the role of these medications in AD treatment and ameliorate the safety and efficacy of AD therapy, although more clinical trials are required to prove their effectiveness. The task force has proposed recommendations to inform best clinical practices on the use of radiation therapy for brain metastases with strong emphasis on multidisciplinary care.
- |||||||||| ketamine / Generic mfg., memantine / Generic mfg.
Journal: Structural insights into binding of therapeutic channel blockers in NMDA receptors. (Pubmed Central) - Jun 22, 2022
The channel blockers form different extents of interactions with the pore-lining residues, which control mostly off-speeds but not on-speeds. Our comparative analyses of the three unique NMDAR channel blockers provide a blueprint for developing therapeutic compounds with minimal side effects.
|
